• Our Company

QuintilesIMS Delivers Integrated Information and Technology Solutions to Drive Healthcare Forward

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.

For more information please visit www.quintilesims.com.

Creating Connections for Healthcare Performance in Australia

Established in New South Wales in the 1970s, QuintilesIMS Australia has one of the most comprehensive offering portfolios in the region. QuintilesIMS’s solutions for the healthcare industry include the pharmacy distribution channel from wholesaler sales to pharmacy through to prescription fulfilment, commercialization enhancement and market research capabilities. In 2013, QuintilesIMS Australia introduced services to pharmacy. These business analytics tools provide a total business view to pharmacy and a foundation for future service development.

During 2013-2015, QuintilesIMS Australia is continuing significant investment in helping clients to gain deeper insight into prescription and consumer health information. This investment will allow the realization of a number of services that address the need for more accurate representation of the healthcare market and the dynamics that influence commercial potential.

The size of the total pharmaceutical market in Australia reached US$12.7 billion in 2013, reflecting a 0.6% market decrease on the previous year. Despite this downturn, according to QuintilesIMS Market Prognosis 2014, the Australian Pharmaceutical Market is expected to grow, averaging a CAGR of 0.5% up to 2018.

An increase in health promotion and disease awareness will boost consumption of medicines in the therapeutic areas targeted in national campaigns. Faster market access for new medicines, under government efforts to operate in accordance with agreements made with industry under the Memorandum of Understanding is an additional growth driver. The expanded and accelerated price disclosure rules will continue to reduce pharmaceutical prices, with the system remaining in place until mid-2014 at least.

In today's highly competitive and complex environment, contact your QuintilesIMS Australia representative to gain greater clarity and stay one step ahead of the competition with the valuable insights gained from QuintilesIMS offerings.